Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KA-3001
- Development stage
- Preclinical
- Lead developer
- KYINNO BIOTECHNOLOGY
- Modality
- Antibody-Based Therapeutics
01
Overview
KA-3001: sourced facts only. name: "In this study, we have developed a bispecific antibody (BsAb), KA-3001, targeting PSMA and human CD28, aiming to enhance T cell activation in the tumor microenvironment." [DOI:10.1158/1538-7445.am2024-2381]; target: "In this study, we have developed a bispecific antibody (BsAb), KA-3001, targeting PSMA and human CD28, aiming to enhance T cell activation in the tumor microenvironment." [DOI:10.1158/1538-7445.am2024-2381]; target: "In this study, we have developed a bispecific antibody (BsAb), KA-3001, targeting PSMA and human CD28, aiming to enhance T cell activation in the tumor microenvironment." [DOI:10.1158/1538-7445.am2024-2381]; developer: "1Kyinno Biotechnology Co., Ltd, Beijing, China." [DOI:10.1158/1538-7445.am2024-2381]; modality: "In this study, we have developed a bispecific antibody (BsAb), KA-3001, targeting PSMA and human CD28, aiming to enhance T cell activation in the tumor microenvironment." [DOI:10.1158/1538-7445.am2024-2381]; stage: "In PBMC humanized immunodeficient mouse tumor models, KA-3001 effectively suppresses the growth of 22Rv1 tumors with or without PD-1 antagonist antibody." [DOI:10.1158/1538-7445.am2024-2381]
02
Targets
CD28 (Cluster of Differentiation 28)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on KA-3001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KA-3001.